Outcome of various treatments for posttransplant hepatitis B virus recurrence

World Journal of Surgery

Volumn 37, Issue 4, 2013, Pages 812-819

  Yi, Nam Joon ^a   Lee, Kwang Woong ^a,b   Kong, Sun Young ^b   Park, Kyoung Un ^c   Lee, Kyoung Bun ^a   Hong, Geun ^a   Han, Sung Sik ^b   Park, Sang Jae ^b   Suh, Kyung Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADENINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; DRUG DERIVATIVE; ENTECAVIR; GUANINE; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; EVALUATION; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADENINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879691024     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-013-1914-z     Document Type: Article

References (27)

1. Wai CT, Lim SG, Tan KC (2000) Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore. Gut 47:741
2. Hwang S, Lee SG, Ahn CS et al (2008) Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl 14:770-778
3. Yi NJ, Suh KS, Cho JY et al (2007) Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 13:451-458
4. Papatheodoridis GV, Cholongitas E, Archimandritis AJ et al (2009) Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 29:1294-1305
5. Chun J, Kim W, Kim BG et al (2010) High viremia, prolonged lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant 10:1649-1659
6. Sorrell MF, Belongia EA, Costa J et al (2009) National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 49:S4-S12
7. Akyildiz M, Karasu Z, Zeytunlu M et al (2007) Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 22:2130-2134
8. Terrault N, Roche B, Samuel D (2005) Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl 11:716-732
9. Gish RG, Lok AS, Chang TT et al (2007) Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 133:1437-1444
10. Sorrell MF, Belongia EA, Costa J et al (2009) National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 150:104-110
11. Han YS, Lee SK, Joh JW et al (2006) Outcomes of hepatitis B virus recurrence after liver transplantation. Transplant Proc 38:2123-2124
12. Neff GW, O'Brien CB, Nery J et al (2004) Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 210:1372-1378
13. Schiff ER, Lai CL, Hadziyannis S et al (2003) Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38:1419-1427
14. Bienzle U, Gunther M, Neuhaus R et al (2002) Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl 8:562-564
15. Starkel P, Stoffel M, Lerut J et al (2005) Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 11:1228-1234
16. Neff GW, Nery J, Lau DT et al (2004) Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacother 38:1999-2004
17. Fung J, Cheung C, Chan SC et al (2011) Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 141:1212-1219
18. Schiff E, Simsek H, Lee WM et al (2008) Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 103:2776-2783
19. Samuel D, Muller R, Alexander G et al (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329:1842-1847
20. Schilling R, Ijaz S, Davidoff M et al (2003) Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 77:8882-8892
21. Thompson AJ, Nguyen T, Iser D et al (2010) Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51:1933-1944
22. Lok AS (2002) Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 8:S67-S73
23. Lok AS (2002) Chronic hepatitis B. N Engl J Med 346:1682-1683
24. Liaw YF (1998) Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 13:14-20
25. Shiota G, Harada K, Oyama K et al (2000) Severe exacerbation of hepatitis after short-term corticosteroid therapy in a patients with "latent" chronic hepatitis B. Liver 20:415-420
26. Faria LC, Gigou M, Roque-Afonso AM et al (2008) Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134:1890-1899 quiz 2155
27. Kiyici M, Yilmaz M, Akyildiz M et al (2008) Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant Proc 40:1511-1517